“Clinical Care Pathway” for Nonalcoholic Fatty Liver Disease

An interdisciplinary panel has published guidance on screening, diagnosis, and management.

Sponsoring Organization: American Gastroenterological Association (AGA)

Background

Because the prevalence of nonalcoholic fatty liver disease (NAFLD) is high in the general population, the AGA convened a multidisciplinary panel to develop an algorithmic “clinical care pathway” for NAFLD that is appropriate for primary care clinicians.

Key Points

Identify “at-risk” patients, who fall into these three groups: (1) type 2 diabetes; (2) two or more metabolic risk factors (i.e., central obesity, high triglycerides, low HDL cholesterol, hypertension, prediabetes); and (3) incidental finding of steatosis on imaging or high alanine or aspartate transaminase (ALT or AST) on laboratory testing.
Screen at-risk patients for alcohol use and check ALT and AST …

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

“Clinical Care Pathway” for Nonalcoholic Fatty Liver Disease

Topics

Background

Key Points

Reviewing Author